Currently, 5 million seniors who reside in the community or assisted living or nursing facilities are affected by Alzheimer's disease and other neurocognitive disorders. They experience various psychiatric symptoms. Also, their family members are stressed from caregiving, and may feel guilty for not doing more.
Methods
We created an innovative nonpharmacological intervention, AlzhaTV to decrease behavioral and psychological symptoms associated with neurocognitive disorders. We offered AlzhaTV to 9 nursing home patients.
Results
In our retrospective examination of this case series, we found AlzhaTV was effective in reducing behavioral and psychological symptoms in patients with neurocognitive disorders. We achieved either dose reductions, discontinuation, or avoided initiating the use of antipsychotic medications and benzodiazepines in nearly all patients.
Conclusions
AlzhaTV may help decrease behavioral and psychological symptoms of dementia and decrease or avoid the use of antipsychotic medications or benzodiazepines. It may help in reducing the overall cost of health care in patients with dementia or neurocognitive disorders. AlzhaTV helps patients stay connected to their families, friends, and their past while bringing them joy in the present. It also helps families and caregivers feel more connected and less helpless.
Get full access to this article
View all access options for this article.
References
1.
SteeleCRonverBChaseGA. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry. 1990; 147: 1049–1051.
2.
HauptMKurzA.Predictors of nursing home placement in patients with Alzheimer's disease. Int J Geriat Psychiatry. 1993; 8: 741–746.
3.
SelbaekGKirkevoldØ, EngedalK.The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes. Int J Geriatr Psychiatry.2007; 22: 843–849.
4.
DouglasSJamesIBallardCNon-pharmacological interventions in dementia. Adv Psychiatr Treat.2004; 10: 171–177.
5.
WangJYuJTWangHF. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015; 86: 101–109.
6.
ShahAAAftabA.Should physicians prescribe antipsychotics in dementia?Psychiatr Ann.2016; 46: 97–102.
7.
SchneiderLSTariotPNDagermanKS; CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006; 355: 1525–1538.
8.
SalzmanCJesteDVMeyerRE. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clinical Psychiatry. 2008; 69: 889–898.
9.
SchneiderLSDagermanKSInselP.Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005; 294: 1934-1943.
10.
DevanandDPMintzerJSchultzSK. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med. 2012; 367: 1497–1507.
11.
BallardCGWaiteJBirksJ.Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 2009; 4: CD003476.
12.
SchneiderLSDagermanKInselPS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006; 14: 191–210.
13.
PorsteinssonAPDryeLTPollockBG; CitAD Research Group. Effect of Citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014; 311: 682–691.
14.
ScitzDPAdunuriNGillSS. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;CD008191.
15.
HenryGWilliamsonDTampiRR. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Demen. 2011; 26: 169–183.
16.
LonerganETCameronMLuxenbergJ.Valproic acid for agitation in dementia. Cochrane Database Syst Rev. 2004;CD003945.
17.
KonovalovSMuraleeSTampiRR. Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. Int Psychogeriatr. 2008; 20: 293–308.
18.
TrinhNHHoblynJMohantyS. Efficacy of Cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003; 289: 210–216.
19.
MaidmentIDFoxCGBoustaniM. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother. 2008; 42: 32–38.
20.
TampiRRTampiDJ. Efficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: a systematic review of randomized controlled trials. Am J Alzheimer's Dis Other Dement. 2014; 29: 565–574.
21.
TampiRRWilliamsonDMuraleeS. Behavioral and psychological symptoms of dementia: part II— treatment. Clin Geriatr. 2011; 19: 2–10.
22.
BrasureMJutkowitzEFuchsE. Nonpharmacologic interventions for agitation and aggression in dementia. Rockville, MD: Agency for Healthcare Research and Quality (US); 2016. Comparative Effectiveness Reviews, No. 177.
23.
RobinsonLHutchingsDCornerL. A systematic literature review of the effectiveness of non-pharmacological interventions to prevent wandering in dementia and evaluation of the ethical implications and acceptability of their use. Health Technol Assess. 2006; 10: iii, ix-108.
24.
LivingstonGKellyLLewis-HolmesE. Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. Br J Psychiatry. 2014; 205: 436–442.
25.
ChenowethLKingMTJeonYH. Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial. Lancet Neurol. 2009; 8: 317–325.
26.
OlazaránJ, ReisbergB, ClareL, . Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy. Dement Geriatr Cogn Disord. 2010; 30: 161–178.
27.
BallardCGO'BrienJTReicheltK. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiatry. 2002; 63: 553–558.
28.
Cohen-MansfieldJMarxMSDakheel-AliM. The use and utility of specific nonpharmacological interventions for behavioral symptoms in dementia: an exploratory study. Am J Geriatr Psychiatry. 2015; 23: 160–170.
29.
VarshneySVarshneyJVarshneyU. AlzhaTV: a smartphone app for managing depression, anxiety, and agitation in dementia patients in nursing homes. Am J Geriatr Psychiatry. 2016; 24: S148–S149.
30.
CummingsJL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997, 48(suppl 6):S10–S16.
31.
CummingsJLMegaMGrayK. The Neuropsychiatrie Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44: 2308–2314.
32.
BurkeWJRoccaforteWHWengelSP. The short form of the Geriatric Depression Scale: a comparison with the 30-Item form. J Geriatr Psychiatry Neurol. 1991; 4: 173–178.
33.
CockrellJRFolsteinMF. Mini-Mental State Examination (MMSE). Psychopharmacol Bull. 1988; 24: 689–692.
34.
VarshneyJUVarshneySMcCallWV. Reliability and validity of co-operation scale in nursing home dementia patients. Control ID: 2848753. Am J Geriatric Psychiatry. 2018; 26: 3(suppl 1):154–156.
